Among 4 analysts covering Callaway Golf (NYSE:ELY), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Callaway Golf had 5 analyst reports since December 18, 2018 according to SRatingsIntel. On Tuesday, December 18 the stock rating was upgraded by Compass Point to “Buy”. KeyBanc Capital Markets maintained the stock with “Buy” rating in Thursday, February 14 report. Berenberg maintained the stock with “Buy” rating in Thursday, February 28 report. See Callaway Golf Company (NYSE:ELY) latest ratings:
28/02/2019 Broker: Berenberg Rating: Buy New Target: $24 Maintain
14/02/2019 Broker: KeyBanc Capital Markets Rating: Buy New Target: $23 Maintain
13/02/2019 Broker: Berenberg Rating: Buy Initiates Coverage On
09/01/2019 Broker: Stephens Rating: Equal-Weight New Target: $17 Initiates Coverage On
18/12/2018 Broker: Compass Point Old Rating: Neutral New Rating: Buy Upgrade
The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock increased 2.23% or $0.24 during the last trading session, reaching $11.02. About 120,805 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 29, 2018 and is uptrending. It has outperformed by 86.16% the S&P500. Some Historical XBIT News: 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTICThe move comes after 7 months positive chart setup for the $397.25 million company. It was reported on Mar, 29 by Barchart.com. We have $11.46 PT which if reached, will make NASDAQ:XBIT worth $15.89M more.
More notable recent Callaway Golf Company (NYSE:ELY) news were published by: Benzinga.com which released: “Callaway Golf (NYSE:ELY) CEO Talks Jack Wolfskin, Epic Flash Driver, How AI Will Change The Industry – Benzinga” on March 04, 2019, also Benzinga.com with their article: “Jim Cramer Shares His Thoughts On Microsoft, Berkshire Hathaway, Callaway Golf And More – Benzinga” published on March 22, 2019, Globenewswire.com published: “New Research Coverage Highlights Callaway Golf, General Electric, Ares Management, Main Street Capital, Public Storage, and Viavi Solutions â€” Consolidated Revenues, Company Growth, and Expectations for 2019 – GlobeNewswire” on March 06, 2019. More interesting news about Callaway Golf Company (NYSE:ELY) were released by: Prnewswire.com and their article: “Francesco Molinari Joins Callaway Golf Tour Staff – PRNewswire” published on March 05, 2019 as well as Benzinga.com‘s news article titled: “Raymond James: Callaway’s Latest M&A Deal ‘Dramatically’ Changes Business (NYSE:ELY) – Benzinga” with publication date: December 05, 2018.
Callaway Golf Company, together with its subsidiaries, designs, makes, and sells golf clubs, golf balls, golf bags, and other golf-related accessories in the United States and internationally. The company has market cap of $1.51 billion. It offers drivers, fairway woods, hybrids, irons, wedges, and putters. It has a 14.74 P/E ratio. The firm also accessories, such as packaged sets, golf gloves, golf footwear, golf apparel, travel gear, headwear, towels, umbrellas, eyewear, and other accessories under the Callaway Golf, Odyssey, and Strata brand names.
The stock increased 0.06% or $0.01 during the last trading session, reaching $15.92. About 847,730 shares traded. Callaway Golf Company (NYSE:ELY) has risen 12.59% since March 29, 2018 and is uptrending. It has outperformed by 8.22% the S&P500. Some Historical ELY News: 20/04/2018 – Callaway Golf Company to Broadcast First Quarter 2018 Financial Results; 22/05/2018 – Callaway Golf Presenting at Conference Tomorrow; 26/04/2018 – Callaway Golf 1Q EPS 65c; 27/04/2018 – CALLAWAY GOLF 1Q EPS 65C, EST. 51C; 26/04/2018 – Callaway Golf Sees 2Q Adj EPS 44c-Adj EPS 48c; 26/04/2018 – Callaway Golf Company Announces Record Net Sales And Earnings For The First Quarter Of 2018 And Significantly Increases Full Year Financial Guidance; 26/04/2018 – Callaway Golf Company Announces Record Net Sales And Earnings For The First Quarter Of 2018 And Significantly Increases Full Ye; 19/04/2018 DJ Callaway Golf Company, Inst Holders, 1Q 2018 (ELY); 26/04/2018 – Callaway Golf 1Q Net $62.9M; 15/05/2018 – Pioneer Investment Management Buys 1.1% of Callaway Golf
Investors sentiment decreased to 1.04 in 2018 Q4. Its down 0.01, from 1.05 in 2018Q3. It turned negative, as 32 investors sold Callaway Golf Company shares while 79 reduced holdings. 43 funds opened positions while 72 raised stakes. 83.68 million shares or 1.88% more from 82.14 million shares in 2018Q3 were reported. Verition Fund Management Llc stated it has 0.04% in Callaway Golf Company (NYSE:ELY). 3.81 million are held by Fmr Limited Liability Com. Gsa Ptnrs Llp stated it has 20,122 shares or 0.04% of all its holdings. Mutual Of America Capital holds 2,180 shares. Blackrock Incorporated reported 13.29 million shares. Wellington Gp Ltd Liability Partnership invested 0% of its portfolio in Callaway Golf Company (NYSE:ELY). Retail Bank Of America De accumulated 527,434 shares. Meeder Asset Mngmt Inc stated it has 14,309 shares or 0.02% of all its holdings. Principal Financial Grp holds 0.01% in Callaway Golf Company (NYSE:ELY) or 811,891 shares. Comerica Bank, a Michigan-based fund reported 86,698 shares. Athena Capital Advsrs Ltd Liability holds 152 shares or 0% of its portfolio. Advsr Asset holds 8,775 shares. Moreover, Jpmorgan Chase has 0% invested in Callaway Golf Company (NYSE:ELY). Virginia Retirement Et Al holds 0.01% or 67,500 shares in its portfolio. Scott Selber invested in 0.87% or 92,748 shares.
Since February 12, 2019, it had 1 buy, and 0 insider sales for $77,500 activity. FLEISCHER RUSSELL L had bought 5,000 shares worth $77,500 on Tuesday, February 12.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “XBiotech up 13% on positive bermekimab data – Seeking Alpha” on March 01, 2019, also Seekingalpha.com with their article: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha” published on March 05, 2019, Streetinsider.com published: “XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD – StreetInsider.com” on March 01, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Benzinga.com and their article: “Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback – Benzinga” published on March 22, 2019 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering – Benzinga” with publication date: March 21, 2019.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $397.25 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.